19:08 , Jan 19, 2018 |  BioCentury  |  Finance

Incubating in China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing...
21:58 , Dec 15, 2017 |  BioCentury  |  Emerging Company Profile

CD38 hat trick

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
23:28 , Oct 31, 2017 |  BioCentury  |  Emerging Company Profile

Two faces of myeloid

Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells. Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived...
04:58 , Sep 22, 2017 |  BioCentury  |  Finance

Mining fungi

Through GV, LifeMine Therapeutics Inc. will have access to big data expertise as it builds out its fungal DNA mining capabilities. LifeMine raised $55 million in a series A round on Sept. 18 led by existing...
19:50 , Aug 4, 2017 |  BC Week In Review  |  Company News

Adimab grants Lilly rights to antibody discovery platform

Adimab LLC (Lebanon, N.H.) granted Eli Lilly and Co. (NYSE:LLY) exclusive rights to an antibody library and non-exclusive rights to Adimab’s antibody discovery platform in all therapeutic areas. Lilly will have an option to receive...
19:27 , Mar 16, 2017 |  BC Innovations  |  Translation in Brief

Lipinski for mAbs

As therapeutic antibodies mature as a modality, Adimab LLC is aiming to streamline discovery by developing a set of standards -- analogous to the "Lipinski rule of five" for small molecules -- that can identify...
19:38 , Mar 10, 2017 |  BC Week In Review  |  Company News

Adimab, Arsanis deal

Adimab granted Arsanis exclusive, worldwide rights to antibodies against respiratory syncytial virus (RSV). Adimab is eligible to receive undisclosed license fees, development milestones and royalties. Arsanis will initially focus on an undisclosed lead RSV antibody...
21:59 , Mar 3, 2017 |  BioCentury  |  Emerging Company Profile

Dragonfly’s trinkets

Dragonfly Therapeutics Inc. is developing trispecific antibodies that direct endogenous NK cells toward tumor cells. By targeting two distinct activating receptors on NK cells, plus a tumor antigen, the antibodies could be more potent than...